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Abstract
Liposomes were proposed as drug vector systems in the treatment of many diseases. 
The following characteristics recommend the liposomes as attractive candidates for drug 
transportation: solubilisation, duration of action, targeting potential and internalisation. 
Methotrexate, a folate antagonist, was originally developed as an antineoplastic agent 
and subsequently used in inflammatory and/or immunosuppressive diseases. Its side 
effects have led researchers to direct their efforts to reduce toxicity, while maintaining 
efficacy of  methotrexate. Liposomes with methotrexate as such, as well as its disodium 
salt, were prepared using two methods. The liposomes were characterized in terms of 
structure, size, degree of poly‐dispersion and encapsulation efficiency. The effect of 
methotrexate incorporated in liposomes has been investigated in vitro on human lym‐
phoblastic cell line K562. Methotrexate incorporated into liposomes moderately reduces 
the proliferation of K562 cells, but significantly inhibits RNA synthesis. The cellular acti‐
vation is probably the main target of the drug and not the neoplastic proliferation of cells. 
The methotrexate liposomes exhibited significant anti‐inflammatory activity and showed 
reduced toxicity. Given that the encapsulating of the drug in vector systems may result in 
the increasing concentration at the site of action, the methotrexate liposomes represent a 
targeted therapy with an optimized therapeutic efficacy—risk toxicity ratio.
Keywords: liposomes, methotrexate, rheumatoid arthritis
1. Introduction
Liposomes have been proposed as drug vector systems in the treatment of many dis‐
eases. Among the drugs proposed to be encapsulated in liposomes, remarkable are 
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drugs used in anti‐fungal therapy (amphotericin B, nystatin, econazole), in antican‐
cer therapy ( doxorubicine, daunorubicin, methotrexate (MTX), cytarabine, vincristine, 
paclitaxel, mitoxantrone), in the treatment of asthma (albuterol) and in the treatment of 
some inflammatory diseases ( clodronate, methotrexate, lactoferrin), in anti‐viral therapy 
(e.g. for the induction of interferon production), as well as for radio diagnostic purpose 
(indium‐111) [1–9].
The following characteristics recommend the liposomes as attractive candidates for the drug 
transportation: solubilisation (the liposomes can solubilize lipophilic drugs that would be 
difficult to administer intravenously), duration of action (the liposomes function as a micro‐
reservoir which gradually release the drug into the body), targeting potential (by coupling of 
some ligands on the liposomes surface, it can direct a drug to a specific target) and internali‐
sation (the liposomes interact with the target cell and may be able to promote intracellular 
transport of some molecules).
Because they are usually prepared from lipids of natural origin, biodegradable and  non‐
toxic, liposomes are useful as drug vector systems that can reduce systemic toxicity [10]. Side 
effects associated with anti‐tumour drugs administered in conventional dosage forms can be 
reduced by encapsulating them in liposomes. Therefore, the encapsulation of medicines in 
liposomes is a tool to increase the therapeutic index by reducing the drug toxicity and target‐
ing the specific cells [11].
Although liposomes were first described by Alec D Bangham in 1965, the first liposomal drug 
product was approved by the Food and Drug Administration (FDA) in 1995 and contains 
the anticancer drug doxorubicin (Doxil®, doxorubicin hydrochloride liposome injection) 
[12]. Currently, several liposome‐based drugs containing antifungal drugs (amphoteri‐
cin B, Ambisome®, Abelcet®, Amphotec®), anticancer drugs (daunorubicine, Daunoxome®; 
 doxorubicine, Doxil®, Lipo‐dox®, Myocet®; cytarabine, Depocyt®) and photosensitizer for 
 photodynamic therapy (verteporfin, Visudyne®) are approved for clinical use, mainly for 
intravenous administration [13].
Methotrexate, a folate antagonist, was originally developed as an antineoplastic agent and sub‐
sequently used in inflammatory and/or immunosuppressive diseases [14]. Among the cyto‐
toxic agents, methotrexate has been widely used as an immunosuppressant in autoimmune 
diseases [15]. In 1951, the proposal for the use of methotrexate in the treatment of rheumatoid 
arthritis was based on its inhibitory effect on the proliferation of lymphocytes and other cells 
responsible for inflammation of the joint [16]. However, by 1980 there have not been reported 
and published any clinical studies regarding the use of methotrexate in rheumatoid arthritis. 
MTX is currently accepted as the most effective and well‐tolerated disease‐modifying anti‐
rheumatic drug (DMARD) for rheumatoid arthritis [17, 18] with certain effects of slowing the 
progression of the disease and reducing mortality rate [19]. The broad spectrum of side effects 
and the relatively high frequency of them have led researchers to direct their efforts to reduce 
toxicity, while maintaining at the same time the therapeutic efficacy of methotrexate. In this 
regard, both alternative routes of administration (especially in the treatment of inflammatory 
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diseases) and new pharmaceutical formulations with methotrexate were investigated. It has 
been suggested that the anticancer drugs formulated in liposomes would be the long‐awaited 
‘magic pill’ for cancer therapy, due to their ability to selectively accumulate in tumours; at the 
same time, toxicological studies indicate that encapsulation in liposomes provides protection 
against the majority of the adverse effects of chemotherapy drugs. On the other hand, lipo‐
somes were shown to give an effective and appropriate delivery of anti‐rheumatoid drugs to 
the synovial fluid [20].
Liposomes with methotrexate as such (further named ‘hydrophobic methotrexate’ lipo‐
somes), as well as its disodium salt (further named ‘hydrosoluble methotrexate’ liposomes), 
were prepared using two methods: the lipid film hydration method and reverse‐phase 
evaporation method (REV). The liposomes were characterized in terms of structure, size, 
and degree of poly‐dispersion and encapsulation efficiency. Methotrexate incorporation into 
liposomes has been achieved by passive loading method which encapsulates the active com‐
pound during liposome formation or in a stage of preparation when the liposomal structure 
is very fluid.
The effect of methotrexate incorporated in liposomes has been investigated in vitro on human 
lymphoblastic cell line K562.
The effects of short‐term therapy with methotrexate incorporated into the liposomes have 
also been demonstrated in an animal model of rheumatoid arthritis.
2. Preparation of methotrexate liposomes
Liposomes are phospholipid vesicles made up of one or more concentric phospholipid bilay‐
ers alternating with layers of aqueous. Phospholipids are a very attractive transport way of 
drugs and other molecules not only because they are able to form lamellar phases but also 
because they are natural components of cell membranes having low allergenic potential; they 
can be metabolized in a manner similar to the endogenous phospholipid membrane and have 
the advantage of structural variability which can be used to modify the physical properties of 
liposomes so as to increase selectivity for target organ.
Liposomal properties depend on both the choice of phospholipids and the addition of sterols, 
particularly cholesterol, and glycolipids [21].
Over time, the size, number of lamellae and the characteristics of the lipid bilayer were 
handled depending on the purpose of the liposome. Thus, conventional liposomes, steri‐
cally stabilized liposomes (‘stealth’ liposomes), cationic liposomes or targeted liposomes 
(by coupling ligands to the surface) have been developed. Sterically stabilized liposomes, 
undetectable (‘stealth’), contain lipid derivatives of a polymer (polyethylene glycol, PEG) 
inserted into the lipid bilayer, which gives them the advantage of the enhanced circulation 
times.
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Conventional liposomes and sterically stabilized liposomes with the following compositions 
were prepared:
1. Phosphatidylcholine (PC)
2. Phosphatidylcholine:cholesterol (PC:CH)
3. Phosphatidylcholine:cholesterol:polyethylene glycol‐2000‐phosphatidylethanolamine 
(PC:CH:PEG2000‐PE).
Liposomes are used to encapsulate both hydrophobic and hydrosoluble drugs within the 
bilayer and the aqueous core, respectively. Consequently, both methotrexate as such (hydro‐
phobic methotrexate liposomes) and its disodium salt (hydrosoluble methotrexate liposomes) 
were encapsulates in liposomes. Methotrexate incorporation into liposomes has been achieved 
by passive loading method which encapsulates the active compound during liposome forma‐
tion or in a preparation stage when the liposomal structure is very fluid [22].
The following weight ratios between the lipid phase and the active substance methotrexate 
were used: PC:MTX 10:1; PC:CH:MTX 10:2:1 and PC:CH:MTX 10:1:1 for conventional lipo‐
somes and PC:CH:MTX:PEG2000 10:1:1:1 for sterically stabilized liposomes [23].
Also, ‘control liposomes’ (or empty liposomes, or liposomes unloaded with methotrexate) 
were prepared using the following compositions: PC or PC:CH (10:1 and 10:2) for conven‐
tional liposomes and PC:CH:PEG2000‐PE (10:1:1) for sterically stabilized liposomes. In order 
to track the cellular internalisation, we prepared the ‘control liposomes’ sterically stabilized 
with the composition PC:PGPH (polyglycerol 12‐hydroxystearic acid ester) (10:1).
Two methods of preparation were used: the lipid film hydration method [24] and reverse‐
phase evaporation method [25–27].
2.1. Lipid film hydration method
The mechanism of liposome formation by lipid film hydration method, combined with extru‐
sion, consists of the following sequence of steps: initially, thin lipid film is hydrated and lipid 
layers become fluid, then, hydrated lipid lamellae are detached and self‐closed, to form large 
multilamellar vesicles. In order to reduce the size, extrusion of the liposomes is performed, 
which determines the conversion of multilamellar liposomes in unilamellar liposomes.
The lipid film hydration method was used for the preparation of liposomes with hydropho‐
bic methotrexate. Soybean lecithin and cholesterol were dissolved in chloroform‐methanol 
(2:1, v/v), then the active substance is added and stirred to mix. The organic solution is then 
 subjected to evaporation under reduced pressure in the rotary evaporator to remove the 
organic solvent. Thin lipid film displayed on the wall’s balloon is hydrated by adding pH 7.4 
phosphate buffer. The resulting dispersion is kept at rest for 48 h.
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2.2. Reverse‐phase evaporation method
Reverse‐phase evaporation method allows to obtain large unilamellar liposomes (or large 
 unilamellar vesicles, LUV), with a significant aqueous compartment. In this process, 
phospholipids are dissolved in an organic solvent or in a mixture of organic solvents. 
Then, the aqueous phase is added to the organic phase. At this stage, phospholipids are 
placed at the interface between two immiscible phases. A W/O emulsion is formed by 
ultra‐sonication or magnetic stirring. The success of emulsification is a fundamental con‐
dition to obtain unilamellar liposomes with high encapsulation capacity. The removal 
of the solvent by evaporation leads to the closeness of the micelles and, consequently, to 
the formation of a gel emulsion. During this step, the micelles are forming monolayers 
surrounding aqueous compartments and aggregate to form a compact gelled network. 
During the next stage, the pressure is reduced to promote the complete evaporation of 
the organic solvent, at which the destructuration of the gel occurs and the monolayers are 
getting closer to form liposomal bilayers. This process can be accelerated by shaking the 
solution using a vortex.
For the preparation of hydrophobic methotrexate liposomes, soya lecithin and cholesterol or 
PEG2000‐PE were dissolved in chloroform‐methanol (2:1, v/v), then the active substance is 
added and stirred to mix. Equal volumes of the organic solution and phosphate buffer solu‐
tion pH 6 were mixed under magnetic stirring until a W/O emulsion was obtained. Organic 
solvents were then evaporated to obtain a gel emulsion. After the destructuring of the gel, 
pH 6 phosphate buffer was added and stirring was continued until the liposomal dispersion 
is formed.
For the preparation of hydrosoluble methotrexate liposomes, soya lecithin and cholesterol 
or PEG2000‐PE were dissolved in chloroform‐methanol (2:1, v/v), and equal volumes of the 
organic solution and sodium salt of methotrexate were mixed under magnetic stirring until 
a W/O emulsion was obtained. Organic solvents were then evaporated to obtain a gel emul‐
sion. After the destructuring of the gel, pH 7.4 phosphate buffer was added and stirring was 
continued until the liposomal dispersion is formed.
2.3. Reducing the size of liposomes and increasing the uniformity of their size by 
extrusion
Since the formed liposomes are heterogeneous in size, a uniform dispersion is obtained by 
extrusion. For particle size reduction, liposome dispersions were passed 10 times through 
a polycarbonate membrane (Whatman Nucleopore® Tch Track Membrane‐E) with a pore 
diameter of 3 μm and then through a membrane with a pore diameter of 100 nm. The pre‐fil‐
tration through a filter membrane with larger pores (3 μm) is necessary to prevent clogging 
of the membrane. In the case of sterically stabilized liposomes, as they have been used in 
studies in vivo, extrusion was carried out through a polycarbonate membrane with a 100‐nm 
pore size.
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3. Characterization of methotrexate liposomes
The liposomes were characterized in terms of structure, shape, size and degree of poly‐ dispersion 
and methotrexate encapsulation efficiency.
Characterisation of the obtained liposomes was pursued as follows:
• The visualisation and the determination of the type of liposomes using enhanced video 
microscopy (VEM) and transmission electron microscopy (TEM);
• The determination of the size and size distribution of liposomes by dynamic light‐ scattering 
technique (DLS);
• The determination of the encapsulation rate and the determination of the content of active 
substance in liposomes.
In addition to the general methods for liposomes characterisation, intracellular liposomes 
transport was studied by fluorescence microscopy, and quantification of cell internalisation 
of ‘control liposomes’ was studied by fluorimetric technique.
3.1. The visualisation and the type of liposomes
Microscopy is a method for observing liposomal dispersion and determining the shape and 
the size of liposomes. The ability of this method to directly visualize colloidal structures in 
real time allows to observe dynamic changes in the number and size of the vesicles and also 
offers the possibility of discovering new structures.
Examination by enhanced video microscopy showed in particular the shape, size and 
state of dispersion, but no information on liposome structure was obtained using this 
technique.
VEM images of methotrexate hydrophobic liposomes prepared by the two methods, the 
hydration of the lipid film and reverse‐phase evaporation, are shown in Figures 1 and 2.
Figure 1. VEM images of hydrophobic MTX liposomes prepared by the method of hydration of the lipid film: 
PC:MTX = 10:1 (a), PC:CH:MTX = 10:1:1 (b), PC:CH:MTX = 10:2:1 (c).
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Hydrophobic methotrexate liposomes prepared by both methods were unilamellar and poly‐
disperse. The presence of cholesterol leads to a decrease of the average diameter of the lipo‐
somes. The ratio PC:CH influences the size of liposomes.
Hydrosoluble methotrexate liposomes were prepared only by the reverse‐phase evaporation 
method due to higher encapsulation of methotrexate. In this case, the same change in size of 
the liposomes in the presence of cholesterol was observed (Figure 3).
Variation of liposomes size depending on the lipid layer composition can be explained by the 
fact that, at the working pH, the phosphatidylcholine polar groups are charged with negative 
electric charges, which cause electrostatic repulsion between them with the formation of large 
vesicles; cholesterol, due to its amphiphilic properties, is inserted between phosphatidylcho‐
line molecules shielding the electrostatic repulsion between the polar groups and thereby 
increase the radius of curvature of the bilayer.
Considering under micron size of the obtained vesicles, transmission electron microscopy 
was also used. The suspension of liposomes was analysed using the negative staining  electron 
Figure 2. VEM images of hydrophobic MTX liposomes prepared by reverse‐phase evaporation method: PC:MTX = 10:1 
(a), PC:CH:MTX = 10:1:1 (b).
Figure 3. VEM images of hydrosoluble MTX liposomes prepared by reverse‐phase evaporation method: PC:MTX = 10:1 
(a), PC:CH:MTX = 10:1:1 (b).
Methotrexate Liposomes - A Reliable Therapeutic Option
http://dx.doi.org/10.5772/intechopen.68520
273
microscopy with 1% phosphotungstic acid. Liposomal dispersions with methotrexate 
(PC:CH:MTX = 10:1:1) were stored at a temperature of 3–5°C and monitored for 3 days (after 
48 h, Figure 4a, and after 72 h, Figure 4b). After 72 h of preparation, TEM images showed a 
reversible coagulation process, unaccompanied by the membrane destruction. This process is 
similar to emulsion‐clotting process which does not cause the emulsion destruction. The pres‐
ence of electrical charges on the surface of liposomes explains their electrostatic stabilisation.
The encapsulation of hydrosoluble methotrexate in the internal aqueous liposomal medium 
results in larger liposomes than those obtained in the absence of MTX (Figure 5).
The same effect was observed for liposomes loaded with hydrophobic MTX prepared using 
pH = 7.4 buffer (Figure 6) due to the solubilisation in the aqueous phase of a part of MTX 
initially encapsulated in liposome membrane. Increasing the size of the liposomes in the pres‐
ence of methotrexate can be explained also by the osmotic pressure. Due to the hydrophobic‐
ity of the lipid bilayer and taking into account that at pH 7.4, both PC and MTX are charged 
with electrical charges of the same sign, methotrexate diffusion through liposomal membrane 
is prevented. The pressure difference on both sides of the liposomal membrane occurs due 
to the difference in the concentration of methotrexate in the inner aqueous phase and in the 
dispersion medium.
Figure 5. VEM images of ‘control liposomes’ (PC:CH) (a) and hydrosoluble MTX liposomes (PC:CH:MTX) (b).
Figure 4. TEM images of the hydrosoluble MTX liposomes, 48 h (a) and 72 h (b) after preparation.
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In order to reduce the solubilisation of hydrophobic methotrexate in the aqueous medium 
at pH 7.4, and to increase the efficiency of encapsulation, hydrophobic methotrexate lipo‐
somes were prepared by reverse‐phase evaporation method, using a pH 6 buffer solution 
as a dispersion medium. TEM images of the liposomes prepared as such are shown in 
Figure 7.
The results of microscopic examination suggested that the presence of methotrexate in the 
liposome membrane does not affect the size of the liposomes. It would be expected that the 
presence of methotrexate in bilayer increases the size of the liposomes. The molecules of 
organic acids with odd number of carbon atoms are not flat, but have a twisted structure and 
are not centre‐symmetrical, but have a binary axis of symmetry. Carboxyl groups are inclined 
at an angle of 60° relative to each other and 30° to the plane of zigzag chain of carbon atoms 
[28]. Given this structure of methotrexate, inserting it between molecules PC would have been 
expected to result in an increase of lecithin vesicle size.
The methotrexate molecule is not placed between the lecithin molecules due to its pronounced 
hydrophobic character but it is encapsulated in the hydrophobic region of the bilayer  leading 
Figure 6. TEM images of ‘control liposomes’ (PC) (a) and hydrophobic MTX liposomes prepared with pH 7.4 buffer 
(PC:MTX) (b).
Figure 7. TEM images of ‘control liposomes’ (PC) (a) and hydrophobic MTX liposomes prepared with pH 6 buffer 
(PC:MTX) (b).
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eventually to an increase in the thickness of the bilayer made, but not in an increase of lipo‐
somes size.
In order to reduce the liposomes size and to increase the uniformity of their size, liposo‐
mal poly‐dispersion was extruded by passing them through polycarbonate membranes with 
different pore diameters: first membrane with a pore diameter of 3  μ m, then a membrane 
with a pore diameter of 100 nm in the case of sterically stabilized liposomes. Liposomes were 
extruded to increase their stability and in order to decrease the size under the diameter of 
capillaries for intravenous administration. Examples of TEM images of the MTX liposomes 
before and after extrusion are shown in Figures 8.
3.2. The determination of the size and size distribution of liposomes
To determine the size and size distribution of the liposomes, dynamic light‐scattering tech‐
nique was used. This technique can be applied to systems in which the average diameter is 
less than 1 μm. The advantage of the DLS to electron microscopy is that information can be 
obtained quickly (minutes) and is less expensive. To determine the size distribution of the 
liposomes by this method, a NICOMP 270 DLS Submicron Particle Sizer (Pacific Scientific® 
Hiac/Royoco Instruments Division) was used.
The decrease in liposomes diameter when the cholesterol was added in the lipid phase 
observed by microscopic techniques was confirmed by the results of the DSL determinations. 
A decrease of approximately 50% in the mean diameter of liposomes was observed for PC:CH 
formula, from 2502.6 to 1450.2 nm.
The increase of liposomes size after hydrosoluble methotrexate encapsulation observed by 
VEM and TEM techniques (Figure 5) is supported by the DLS results (Figure 9). It is noted that 
the average diameter of the PC:CH:MTX liposomes (4893.2 nm) is superior to that obtained 
for PC:CH liposomal dispersion (2502.6 nm).
3.3. The determination of the encapsulation rate
Methotrexate liposome encapsulation efficiency was estimated by the determination of 
loading yield. Load yield is the ratio of the amount of active substance encapsulated in 
Figure 8. TEM images of PC:CH:MTX liposomes before (a) and after (b) extrusion.
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liposomes and the initial amount of active substance and is calculated using the following 
formula:
  R 
i
   =    C f  __ 
 C 
0
 
× 100 (1)
where C
f
 is the concentration of active substance in the liposome dispersion after the removal 
of unloaded active substance, and C
0
 is the concentration of active substance in the lipid mix‐
ture used for liposomes preparation.
In order to determine the concentration of active substance in the liposome dispersion 
(C
f
), the removal of the unloaded active substance was done by dialysis for hydrosoluble 
methotrexate liposomes and by Sephadex gel filtration for hydrophobic methotrexate 
liposomes.
The dialysis process was monitored by the UV spectrophotometric determination of the 
methotrexate in dialysate (‘washing water’) in order to confirm that all the unloaded metho‐
trexates were removed (Figure 10).
After the removal of unloaded active substance, the liposomal dispersion was subjected to 
lysis with Triton X‐100 and methotrexate was quantified by high‐performance liquid chroma‐
tography (HPLC).
The efficiency of methotrexate encapsulation, measured by loading yield, was similar for 
hydrosoluble methotrexate liposomes and hydrophobic methotrexate liposomes. However, in 
the case of hydrophobic methotrexate liposomes slightly higher loading yields were obtained 
when cholesterol is added in the lipid layer.
Figure 9. Histogram of PC:CH:hydrosoluble MTX liposomal dispersion.
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The electric charge of liposomes is a predictive factor of their lifecycle. Preliminary studies per‐
formed on liposomes showed that the presence of lipids with negative electric charge leads to 
a reduced elimination of the encapsulated substance. The low permeability for hydrosoluble 
methotrexate of the anionic liposomal membrane explains the high encapsulation efficiency 
obtained. At the same time, the presence of structures with a large interfacial area per volume 
unit (cubosomes and hexasomes) in the colloidal dispersions obtained using REV causes a 
higher encapsulation of hydrophobic substances.
3.4. The determination of content of active substance in liposomes
For the quantitative determination of methotrexate, the liposomal dispersion was sub‐
ject to ultracentrifugation and the active substance was determined by HPLC after 
the liposomes lysis with Triton X100. Chromatographic conditions were as follows: 
HPLC Millenium Waters, Spherisorb 5 ODS 250 × 4.6 mm column, mobile phase 5% 
 tetrahydrofuran in 0.05 M sodium dihydrogen orthophosphate buffer (pH 4.85), flow rate 
1.0 mL/min, 20 μL injected volume, UV detection at 313 nm. The concentration of metho‐
trexate in the liposomal dispersion was calculated based on the methotrexate peak area 
and the obtained calibration curve. The selectivity of the method for the determination 
of methotrexate in liposomes was demonstrated by analysis of MTX‐unloaded liposomes 
(‘ control liposomes’). The lipids contained in the liposome membrane do not interfere 
with methotrexate.
Figure 10. UV‐spectrum of methotrexate in dialysate (‘washing water’).
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The average methotrexate concentration measured was 196 mg/mL for water‐soluble meth‐
otrexate liposomes (Figure 11) and 200 mg/mL for hydrophobic methotrexate liposomes 
(Figure 12).
3.5. Intracellular transport of liposomes studies
Studies of the interaction between liposomes and cells are of particular importance in 
order to develop liposomes as vectors with high efficiency for delivering drugs to cells. 
Therefore, the development of liposomal systems as drug carriers requires detailed under‐
standing of interaction mechanisms between cells and these transporters. Some studies 
have indicated that the in vitro uptake of the liposomes depends on the cell type [29, 30], 
but the factors that are involved in this uptake are not fully understood. In general, it is 
believed that the uptake of the liposomes is mediated by nonspecific adsorption to the cell 
surface [31].
Figure 11. Chromatogram of hydrosoluble methotrexate liposomes.
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Given the importance of the liposomes uptaking by macrophages to the elimination from the 
bloodstream after liposomes intravenous injection, we studied the uptake and the quantifi‐
cation of internalisation of liposomes with different compositions of lipid bilayer by macro‐
phages from tumour line RAW267.4.
The internalisation of the following types of unloaded liposomes was studied: conven‐
tional liposomes containing phosphatidylcholine, steric‐stabilized liposomes containing 
phosphatidylcholine, cholesterol, polyethylene glycol 2000 phosphatidylethanolamine 
Figure 12. Chromatogram of hydrophobic methotrexate liposomes.
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(PC:CH:PEG2000‐PE) and PC:PGPH. The cells were incubated for 2 h at 37°C with the  Dil‐
labelled liposomes.
3.5.1. Visualisation of the liposomes internalisation
The internalisation of the methotrexate‐unloaded liposomes by macrophages of murine 
tumour line RAW267.4 was visualized by fluorescence microscopy, using 1,1’‐ dioctadecyl‐ 
3,3,3’,3’‐tetramethylindocarbocyanine perchlorate (Dil) as a lipophilic tracer. Images were 
acquired using a Nikon microscope, in phase contrast or epifluorescence, with a filter that 
allows 530‐nm excitation and observation of emitted fluorescence at 580 nm. Intracellular 
point‐like fluorescence is observed, indicating that the liposomes are  internalized (Figure 13) 
[32].
3.5.2. Quantification of liposomes internalisation
Quantitative estimation of the ability of RAW 264.7 tumour macrophages to uptake of various 
types of liposomes was assessed by fluorimetric measurements. For this purpose, cells were 
incubated for 2 h at 37°C with methotrexate‐unloaded liposomes, labelled with fluorescent 
Dil tracer (1 μmol liposomes/106 cells). After incubation, the liposomes bounded to cell sur‐
face were removed by washing with cold PBS buffer.
After washing with trypan blue solution (for complete quenching of extracellular fluo‐
rescence), the emitted fluorescence was measured at 580 nm after excitation at 530 nm of 
samples, using a TECAN spectrofluorimeter. The degree of internalisation of the liposomes 
(phospholipid nmol/106 cells) was calculated using the standard curve obtained from known 
concentrations of fluorescent liposomes.
The results showed a low uptake of liposomes containing polyethylene glycol‐2000‐phos‐
phatidylethanolamine (PEG2000‐PE) compared to that of conventional liposomes (PC) or 
PC‐PGPH liposomes (Figure 14). One possible explanation would be that the presence of 
PEG2000 on the surface of steric stabilized liposomes hinders their interaction with cells 
through the barrier formed by hydration of the polymer [32].
Figure 13. Phase contrast images (A) and fluorescence images (B) obtained in RAW 264.7 macrophages incubated for 2 h 
at 37°C with PC liposomes, labelled with Dil (20 × objective).
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4. In vitro effects of MTX liposomes
The immunosuppressive action exerted in vitro by MTX‐loaded liposomes was studied.
We compared the effect of hydrosoluble and hydrophobic MTX liposomes (dispersion 200 mg 
MTX/mL) and MTX solution for injection (concentration 200 mg MTX/mL) on the proliferative 
capacity of human lymphoblastic cells K562. The preparation and characterisation of MTX‐
loaded liposomes are presented in Sections 2 and 3.
The human lymphoblastic K562 cell line, purchased from ECACC (the European Collection 
of Cell Cultures), maintained by in vitro cultivation, has been used. Colchicine (standard 
 microtubule disrupter) at a concentration of 10 μM was used as an inhibitor of cell metabolism. 
Cell proliferation was measured by the MTS reduction test by using CellTiter 96® AQueous 
Non‐Radioactive Cell Proliferation Assay kit (detects the number of viable cells and, con‐
sequently, cell multiplication) (Promega Corporation). The cell activation/proliferation was 
measured by the tritium‐labelled uridine (3H‐Urd) incorporation test which detects RNA 
synthesis requiring uridine incorporation via the salvage pathway of nucleotide biosynthesis. 
The cellular membrane integrity was indirectly evaluated as lactate dehydrogenase (LDH) 
release, by using Cytotox96® NonRadioactive Cytotoxicity Assay kit (Promega Corporation).
The effect exerted by MTX was calculated as the ratio between the values obtained for MTX 
and the control value.
Experimental data indicate that MTX solution for injection inhibits neoplastic multiplication 
(data not shown) and RNA synthesis (Figure 15) in lymphoblastic K562 cells, without notably 
disturbing membrane integrity evaluated as LDH release.
Figure 14. Internalization of PC, PC:PGPH, PC:CH:PEG‐PE liposomes by murine macrophages RAW 264.7 after the 
incubation with 1 μmol liposomes/106 cells Phase contrast images (A) and fluorescence images (B) obtained in RAW 
264.7 macrophages incubated for 2 h at 37°C with PC liposomes, labelled with Dil (20 × objective).
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PC and PC:CH liposomes do not alter significantly the multiplication of K562 cells, but, when 
loaded with hydrophobic MTX, they tend to hold down the proliferation of tumour cells 
(Figure 16). These results are confirmed by those obtained in the evaluation of RNA synthesis 
by the tritium‐labelled uridine radionuclide technique. Thus, while the unloaded liposomes 
(PC and PC:CH) tend to stimulate the RNA synthesis, the corresponding MTX‐loaded lipo‐
somes clearly induce RNA synthesis arrest (Figure 17).
The increase of the quantity of liposomal dispersion (treating the cells with a double amount 
‘2×’ of liposomal dispersion) does not significantly influence the MTX inhibitory effect. It is 
worth noticing that hydrosoluble MTX effect (as solution for injection) is also independent on 
the drug concentration in the range of 0.001–10 μg/mL (data not shown).
Figure 15. The effect exerted in vitro by MTX solution for injection on RNA synthesis by K562 cells.
Figure 16. The effect exerted in vitro on the multiplication of K562 cells by liposomes loaded with hydrophobic MTX, 
compared to unloaded liposomes. Cell proliferation has been evaluated by MTS reduction test.
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The inhibitory effect of hydrosoluble or hydrophobic MTX‐loaded liposomes on K562 cell 
multiplication is comparable. However, hydrophobic MTX‐loaded liposomes have a little 
more intense inhibitory effect compared to hydrosoluble MTX‐loaded liposomes.
The results indicate that hydrophobic MTX loaded in liposomes tends to restrain the tumoural 
multiplication of K562 cells and clearly inhibits RNA synthesis, suggesting that activation 
events are primarily the target of the drug, and not the neoplastic proliferation of lympho‐
blasts. In addition, the hydrophobic form of MTX loaded in liposomes acts similar to the 
hydrosoluble one.
5. Investigation of the effects of short‐term therapy with methotrexate 
incorporated into the liposomes in an animal model of rheumatoid 
arthritis
Rheumatoid arthritis is a chronic, complex, autoimmune disease with plurifactorial etiology. 
It is characterized by hyperplasia of the synovium of the joint cartilage [33], the infiltration of 
the synovial cavity with inflammatory cells [33, 34], the presence of autoreactive lymphocytes 
[35–37] and antibodies with different specifications [38], events that culminates in the gradual 
erosion of the cartilage/bone and a number of serious extra‐articular manifestations [39].
Methotrexate is one of the most widely used disease‐modifying anti‐rheumatic drugs 
(DMARDs) in the treatment of rheumatoid arthritis. Although the precise mechanism of 
action of folate antagonist MTX in the treatment of rheumatoid arthritis is yet unclear [40], the 
effectiveness of methotrexate is associated with its cytotoxic and anti‐inflammatory effects. 
Clinical and experimental evidence sustain that low‐dose MTX has anti‐inflammatory effects 
and a subtle immunomodulatory action [16, 41]. Low dose of methotrexate, orally adminis‐
trated, weekly, effectively suppresses inflammation in rheumatoid arthritis [42]. However, 
Figure 17. The effect exerted in vitro on the multiplication of K562 cells by liposomes loaded with hydrophobic MTX, 
compared to unloaded liposomes. Cell proliferation has been evaluated by the tritium‐labelled uridine incorporation 
test. The effect has been assessed comparatively to colquicine antimitotic standard.
Liposomes284
systemic toxicity, manifested for instance by stomatitis, nausea, bone marrow depression and 
liver damage, may limit oral administration of the drug [43].
Methotrexate has also been administered to control intra‐articular synovitis in the joints of 
arthritic patients, but the results have been disappointing due to rapid clearance of the drug 
from the joint [44].
In order to localize the drug to the site of action and reduce the systemic toxicity, the use of 
liposomes or polymeric microparticles as carriers for drug delivery systems synovial space 
was proposed.
Effects of short‐term therapy with methotrexate incorporated into the liposomes have also 
been investigated in an experimental model of arthritis‐type inflammation‐induced with 
Freund’s adjuvant.
Freund’s adjuvant‐induced arthritis in the rat is one of the most important experimental mod‐
els of immune chronic inflammation, with pharmacological relevance in human rheumatoid 
arthritis. It is most commonly used experimental model for rheumatoid arthritis in screening 
programmes aimed at finding new‐arthritic inflammatory drugs [45].
In a Wistar rat model of arthritis (adjuvant Freund induced), the therapeutic effect and tox‐
icity of MTX as solution for injection or hydrosoluble MTX and hydrophobic MTX‐loaded 
liposomes have been studied [32, 46]. Three different doses of MTX preparations have been 
administered (i.v.) weekly for 21 days: 0.2. mg/b.w., 0.3 mg/b.w and 0.4 mg/b.w.
The induction of arthritis with Freund’s adjuvant and its characterisation was based on the 
evaluation of the primary oedema due to inflammation (injected paw) and the secondary 
inflammation (paw contralateral, not injected), using a plethysmometer device (Ugo Basile, 
Italy) 7 days and 14 days after administration of CFA. The threshold pain response was also 
assessed after 21 days using an analgesy metre, according to the method of Randall‐Selitto 
[47]. Before the injection of Freund’s adjuvant, and 7, 14 and 21 days after induction of arthri‐
tis the mobility scale, posture and joint stiffness were evaluated [48]. In addition, the X‐ray 
examination 21 days after administration of CFA has been performed to evaluate the inflam‐
mation CFA induced.
The effect of MTX treatment was assessed as threshold of pain sensitivity (Randal‐Sellito test) 
7, 14 and 21 days of MTX administration, as well as by radiological evaluation 21 days of MTX 
administration.
The induction of arthritis by Freund adjuvant was confirmed by the statistical results [t‐Student 
test and analysis of variance (ANOVA)] of the inflammatory oedema assessment, the clinical 
assessment and the behaviour of animals (with mobility and posture significantly lower and 
a marked increase of stiffness), as well as the radiological evaluation of the joints (symmetric 
arthritogenic disturbances were present after 21 days) [32]. In addition, a marked increase in 
sensitivity to paw pressure was seen in the affected limb.
A dose‐dependent reduction of pain sensitivity in all groups of animals treated with 
MTX has been shown. In addition, the intensity of the therapeutic effect increased  during 
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 treatment (the marked effect has been observed after 21 days of MTX treatment). The 
effect of MTX treatment has been assessed from the baseline values of the pain sensitivity 
(determined by Randal‐Sellito test) and has been calculated after 7, 14 and 21 days of MTX 
treatment.
The results of the study indicated that the therapeutic effect of MTX liposomes is superior 
to that of MTX solution for injection. At the highest dose administered (0.4 mg/kg), the 
 therapeutic effect of hydrosoluble and hydrophobic MTX liposomes is comparable, while 
at intermediate and low dose, the effect of hydrophobic MTX liposomes is higher than 
that of the hydrosoluble MTX liposomes. Based on the linear relationships between the 
MTX effect and log D (dose), ED
50
 values have been calculated (Table 1). Thus, the lowest 
efficacious doses of MTX were obtained at all times of the treatment for the MTX‐loaded 
liposomes. The results are in agreement with recent data indicating that MTX encapsulated 
in liposomes, in contrast to free and generic MTX, proved to have a higher anti‐inflam‐
matory and  anti‐ angiogenic efficacy in antigen‐induced arthritis model in female C57/Bl6 
mice [49].
The immune status of animals was evaluated 7 and 14 days after treatment discontinuation 
by the following parameters: number of peripheral leucocytes, relative weight of spleen (the 
ratio spleen weight/body weight), number of splenocytes and the activation potential of 
 splenocytes in vitro treated with polyclonal mitogen concanavalin A (ConA) determined by 
the tritium‐labelled uridine incorporation test [50].
Hydrosoluble MTX liposomes particularly tend to enhance the peripheral granulocytes 
 percentage on behalf of the monocyte proportion. Liposome‐targeted MTX induces a drop of 
the monocytes percentage at lower doses than the MTX solution for injection [32]. The men‐
tioned effect ceases 14 days after therapy discontinuation. The effect is less obvious in the case 
of hydrophobic MTX liposomes. While peripheral monocytes percentage decreases shortly 
after the withdrawal of the therapy with MTX liposomes, a tendency of up‐regulation was 
noticed 14 days after. Peripheral leukocytes react to lower doses of MTX loaded in liposomes, 
as compared to MTX solution for injection.
Animals treated with MTX liposomes present lower values of the relative spleen weight. This 
effect is reversible after 14 days since therapy withdrawal. Similar effects are exerted only by 
MTX treatment ED
50
 (mg/kg)
7 days of treatment 14 days of treatment 21 days of treatment
Hydrophobic MTX 
liposomes
0.338 0.272 0.258
Hydrosoluble MTX 
liposomes
0.363 0.337 0.285
MTX solution for injection 
solution
‐ 0.423 0.387
Table 1. ED
50
 of MTX, determined on the base of pain sensitivity for each group of animal.
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high doses of MTX solution for injection. The clinical significance of the registered decrease of 
the relative spleen weight is unclear.
The intermediate doses of MTX‐loaded liposomes increase the number of spleen leukocytes, 
probably on behalf of the peripheral ones.
All MTX formulations induce in vivo activation of splenocytes, but only MTX‐loaded liposomes 
restrain the activation potential of splenocytes to exogenous polyclonal mitogens. Seven days 
after therapy withdrawal, splenocytes are basically activated in the absence of exogenous 
Figure 18. The effect exerted in vivo by MTX on the proliferation capacity of the splenic rat lymphocytes (counts per 
minutes, the tritium‐labelled uridine incorporation test); (a) 7 days after therapy withdrawal; (b) 14 days after therapy 
withdrawal. Legend: The treatment of animal groups: 1;2;3—hydrosoluble MTX‐loaded liposomes (0.2;0.3;0.4 mg/kg b.w); 
4;5;6—hydrophobic MTX‐loaded liposome (0.2;0.3;0.4 mg/kg b.w.); 7;8;10—MTX solution for injection (0.2;0.3;0.4 mg/kg 
b.w.); 9—control (liposomes, 0.1 mL/100 g/kg b.w.).
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stimuli, but the effect is not persistent. Only the MTX‐loaded liposomes exert an immuno‐
suppressive action by limiting the ex vivo response of splenocytes to ConA. In this case, an 
anergic state of splenocytes seems to be triggered. Fourteen days after treatment discontinu‐
ation, all investigated MTX formulations inhibit splenocytes response to ConA. Accordingly, 
MTX liposomes exert a lasting antiproliferative action at critical doses. It is worth noticing 
that low and high doses of hydrosoluble MTX liposomes induce splenocytes anergy, namely 
activation of resting cells and reduced responses ex vivo to Con A. Hydrophobic MTX‐loaded 
liposomes seem to be most efficacious in restraining splenocytes activation.
The results indicate that MTX loaded in liposomes has a more evident impact on the immune 
status than MTX solution for injection, and hydrophobic MTX incorporated in liposomes 
seems to be active at the lowest doses (Figure 18).
The evaluation of the haematological and biochemical parameters indicates a low toxic effect 
of MTX in arthritic rats in the applied treatment regimen. Erythrocyte count was not sig‐
nificantly affected and between erythrocyte parameters series good correlation (correlation 
coefficients of >0.90) was found. Transaminases activities were weak and irregularly affected, 
registering slight increases (especially AST) at highest MTX doses 7 days after the last admin‐
istration. The creatinine and urea serum levels were not significantly affected [32].
MTX treatment induced discrete to moderate and reversible histopathological changes in the 
liver and the kidney. However, a more pronounced impairment in the kidney (glomerular 
stasis and the increase of the vascular network volume, as a result of circulation disturbances, 
as well as tubular nephritis and medullary mononuclear cell infiltration), depending on the 
type of treatment (MTX liposomes or MTX solution for injection) and of the administered 
dose [46], has been noticed.
6. Conclusion: key results
Several types of poly‐disperse liposomal systems containing both hydrosoluble methotrex‐
ate and hydrophobic methotrexate were prepared by two methods: lipid film hydration and 
reverse‐phase evaporation. The last one was selected due to the shorter working time and 
the higher encapsulation efficiency. The liposomal poly‐dispersion was extruded to obtain a 
liposomal monodispersion. MTX liposomes were characterized by VEM, TEM and DLS. The 
obtained liposomes had the diameters of microns size. The unentrapped drug was removed 
and the concentration of entrapped MTX was chromatographically determined. The encapsu‐
lation efficiency was satisfactory and similar for PC:MTX (10:1) liposomes and for PC:CH:MTX 
(10:1:1) liposomes. The presence of CH in liposomal membrane increases the rigidity and the 
hydrophobicity of the membrane. A higher hydrophobic character of liposomal membrane 
means a larger loading efficiency of hydrophobic MTX.
Hydrophobic MTX loaded in liposomes tends to restrain the tumoural multiplication of K562 
cells and clearly inhibits RNA synthesis, suggesting that activation events are primarily the 
target of the drug, and not the neoplastic proliferation of lymphoblasts.
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The methotrexate liposomes exhibited significant anti‐inflammatory activity and showed 
reduced toxicity. Given that the encapsulating of the drug in vector systems may result in 
the increasing concentration at the site of action, the liposomes with methotrexate represent a 
targeted therapy with an optimized therapeutic efficacy—risk toxicity ratio.
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